Cagrilintide is a long-acting amylin receptor agonist currently in active clinical development for obesity and type 2 diabetes, often studied in combination with GLP-1 agonists. As an RUO compound, it is used in research examining amylin receptor signalling, satiety regulation, and glucagon suppression pathways. Demand is growing rapidly among CROs focused on metabolic disease pharmacology. Purity independently verified, supplied lyophilised. For research use only.

Why customers choose us — benefits and guarantees.

Delivery times, returns policy and related info.